[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370458-105":59,"doc-detail-370458-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-current-landscape-of-gastric-cancer-and-gastroesophageal-junction-cancer-diagnosis-and-treatment-in-china-a-comprehensive-nationwide-cohort-analysis","The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China - a comprehensive nationwide cohort analysis","","Large-scale comparative evidence on gastric cancer outcomes across China remains limited despite rising incidence and substantial morbidity and mortality. This nationwide cohort analysis uses data from the National Cancer Information Database covering 220,304 patients treated in 53 leading hospitals across 27 provinces. It evaluates diagnosis patterns, neoadjuvant and adjuvant strategies, management of progressive stages, and alignment with current Chinese guidelines. Results report stage I–II increases, immunotherapy uptake, and measured 1- to 5-year survival rates by stage.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-current-landscape-of-gastric-cancer-and-gastroesophageal-junction-cancer-diagnosis-and-treatment-in-china-a-comprehensive-nationwide-cohort-analysis/370458/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-current-landscape-of-gastric-cancer-and-gastroesophageal-junction-cancer-diagnosis-and-treatment-in-china-a-comprehensive-nationwide-cohort-analysis/370458.png","ImageObject",300,407,{"name":92,"@type":93},"Rhys","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What dataset and patient coverage were used in the nationwide cohort analysis?","Question",{"text":113,"@type":114},"The study used a large-scale dataset from the National Cancer Information Database, including 220,304 patients from 53 leading hospitals across 27 provinces in China.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How did treatment strategies and immunotherapy use vary across treatment lines and stages?",{"text":118,"@type":114},"The analysis evaluated neoadjuvant and adjuvant therapies and management for progressive stages, reporting immunotherapy proportions for first- and second-line treatments in late-stage gastric cancers and for neoadjuvant and adjuvant settings.",{"name":120,"@type":111,"acceptedAnswer":121},"What survival outcomes did the study report, and how did they differ by stage?",{"text":122,"@type":114},"It reported 1-, 2-, 3-, 4-, and 5-year survival rates overall, and also presented 5-year survival rates across stages I–IV, showing substantial stage-related differences.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},370458,1790781553,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Chen et al. Journal of Hematology & Oncology (2025) 18:42 [https://doi.org/10.1186/s13045-025-01698-y](https://doi.org/10.1186/s13045-025-01698-y)  \nJournal of Hematology & Oncology  \nRESEARCH Open Access  \nThe current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China:  \na comprehensive nationwide cohort analysis  \nYang Chen 1*†, Keren Jia 1,2†, Yi Xie 1†, Jiajia Yuan 1, Dan Liu 1, Lei Jiang 1, Haoxin Peng 1, Jia Zhong3, Jian Li 1, Xiaotian Zhang 1 and Lin Shen 1*  \nAbstract  \nBackground Gastric cancer is the fifth most common cancer globally and is associated with significant morbidity and mortality. Despite its alarming prevalence, limited comparative evidence exists on its treatment efficacy and prognosis across diverse China populations.  \nMethods To address this, our study used a large-scale dataset from the National Cancer Information Database, including data from 220,304 patients from 53 leading hospitals across 27 provinces in China.  \nResults From 2017 to 2023, early-stage (Stages I-II) gastric cancer diagnoses increased to 35. 63% of all cancer cases. Our study evaluated the neoadjuvant treatment strategies, adjuvant post-operative therapy, first-and secondline management for progressive stages, alongside current gastric cancer treatment guidelines in China. Notably, immunotherapy accounted for 16. 17% and 23. 28% of first-and second-line treatments for late-stage gastric cancers, and 14. 56% and 5. 00% for neoadjuvant and adjuvant therapies, respectively. Analysis of survival rates revealed that the 1-, 2-, 3-, 4-, and 5-year survival rates were 74 . 07%, 54 . 89%, 44 . 21%, 37 . 97%, and 33 . 53%, respectively. The 5-year survival rates across stages I-IV were 85 . 07%, 49 . 34%, 35 . 56%, and 13. 15%, respectively.  \nConclusions These findings offer critical insights into the current state of gastric cancer treatment in China and can inform future initiatives to improve therapeutic outcomes for patients with gastric cancer.  \nKeywords Gastric cancer, Stage at diagnosis, Treatment regimen, Immunotherapy, Survival  \n†Yang Chen, Keren Jia andYi Xie contributed equally to this work.  \n*Correspondence:  \nYang Chen [Yang_chen@bjcancer.org](Yang_chen@bjcancer.org)[ ](Yang_chen@bjcancer.org)Lin Shen [shenlin@bjmu.edu.cn](shenlin@bjmu.edu.cn)  \n1Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China 2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA  \n3Analysis Group, Boston 02119, USA  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nChen et al. Journal of Hematology & Oncology (2025) 18:42  \nBackground  \nGastric cancer (GC) is the fifth leading cause of cancerrelated mortality globally [1], with China contributing 70% and 50% of new cases of cardia and non-cardia GC, respect","cbCaih1BdgvkS7MQ","https://ap.wps.com/l/cbCaih1BdgvkS7MQ","pdf",1453406,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n# Incidence, risk factors, and changing trends\n# Current standard of care","[{\"question\":\"What dataset and patient coverage were used in the nationwide cohort analysis?\",\"answer\":\"The study used a large-scale dataset from the National Cancer Information Database, including 220,304 patients from 53 leading hospitals across 27 provinces in China.\"},{\"question\":\"How did treatment strategies and immunotherapy use vary across treatment lines and stages?\",\"answer\":\"The analysis evaluated neoadjuvant and adjuvant therapies and management for progressive stages, reporting immunotherapy proportions for first- and second-line treatments in late-stage gastric cancers and for neoadjuvant and adjuvant settings.\"},{\"question\":\"What survival outcomes did the study report, and how did they differ by stage?\",\"answer\":\"It reported 1-, 2-, 3-, 4-, and 5-year survival rates overall, and also presented 5-year survival rates across stages I–IV, showing substantial stage-related differences.\"}]","The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China - a comprehensive nationwide cohort analysis | PDF",1790188645,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c2cd76b68a7386a06b052e5b1d332a3.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52ee214b12481eecc344d6d712565238.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/529db3b414e8a31970c2e92b4ee0f017.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1f51993894986bd5d279cf2a8149b60.webp",980,1306]